Chemotherapy and Drug Information

Recently Discovered microRNA Controls Response to Oxaliplatin in Colorectal Cancer

Danish researchers identified a microRNA shown to predict whether a patient with colorectal cancer would be resistant to oxaliplatin treatment, a discovery that holds promise of improving both current treatment options and development of future treatment strategies.

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).

Managing Toxicity Risks of Dose-Dense Chemotherapy in the Obese

Managing Toxicity Risks of Dose-Dense Chemotherapy in the Obese

Risks for severe toxicities in obese patients receiving dose-dense chemotherapy are associated with measures used to determine dose, according to a retrospective evaluation of select participants in the GAIN study.

Hyper-CVAD + Ponatinib May Be Superior to Hyper-CVAD + Dasatinib in Ph+ ALL

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.

Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of Trastuzumab

Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of Trastuzumab

Therapies targeting ErbB2 (HER2), such as trastuzumab (Herceptin), are often associated with cardiovascular side effects. ErbB2 was recently found to also be expressed by vascular endothelial cells, and is an example of how tissue growth and blood vessel patterning are integrated at the molecular level.

Administering Mannitol With Hydration and Premeds

Administering Mannitol With Hydration and Premeds

At my current clinic, hydration and mannitol are administered before premedications on a cisplatin regimen; at previous clinic, premeds and hydration were administered before mannitol. Does it make a difference?

Cognitive Impairment Common With Adjuvant Therapy in Older Patients With Early Stage Breast Cancer

Cognitive Impairment Common With Adjuvant Therapy in Older Patients With Early Stage Breast Cancer

Cognitive decline associated with adjuvant chemotherapy was more likely to occur in older patients, particularly those whose treatment included docetaxel.

Factors That Determine Sequence of Administration for Multiple Chemotherapeutic Agents

Factors That Determine Sequence of Administration for Multiple Chemotherapeutic Agents

Chemotherapy agents are sometimes required to be administered in a specific sequence. What factors influence the need to follow a specific sequence?

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.

Mimicking Fasting During Chemotherapy Enhances T Cell Activity in Preclinical Study

Fasting during chemotherapy treatment may increase the presence of cancer-killing T cells, according to recent study data.

Stat Consult Slideshows

Fluorouracil (5-FU)

This slideshow reviews fluorouracil (5-FU), indicated for palliative treatment of breast cancer, colorectal cancer, gastric cancer, and carcinoma of the pancreas; also adjuvant treatment of colorectal cancer.

Netupitant/Palonosetron (Akynzeo)

This slideshow reviews netupitant/palonosetron (Akynzeo), indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy.

Bevacizumab (Avastin) - cervical cancer

This slideshow reviews bevacizumab (Avastin), indicated for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.

To view all content in our Stat Consult section, please click here.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs